Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Lymphangioleiomyomatosis × saracatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2 Stomach Neoplasms 1 Solid Tumor 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Lymphangioleiomyomatosis 1 Lung Neoplasms 1 Liver Neoplasms 1 Colonic Neoplasms 1 Choriocarcinoma 1 Cholangiocarcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Sirolimus 2 temsirolimus 1 saracatinib 1 Valproic Acid 1 Immunoglobulin G 1 Imatinib Mesylate 1 Hydroxychloroquine 1 Disulfides 1 Cetuximab 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02116712 2016-11-30

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Baylor College of Medicine

Phase 1 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡